cancerspЮжно-Российский онкологический журнал/ South Russian Journal of CancerSouth Russian Journal of Cancer2686-9039АНО "Перспективы онкологии"10.37748/2686-9039-2022-3-3-5cancersp-164Research ArticleОбзорREVIEWЭволюция лекарственного лечения классической лимфомы ХоджкинаEvolution of drug therapy for classical Hodgkin lymphomahttps://orcid.org/0000-0003-0843-6012СаманеваН. Ю.SamanevaN. Y.

Саманева Наталья Юрьевна – к.м.н., младший научный сотрудник отдела лекарственного лечения опухолей, врач-онколог отделения онкогематологииSPIN: 1181-0659AuthorID: 734488ResearcherID: AAH-7905-2019Scopus Author ID: 57192874030

344037, г. Ростов-на-Дону, ул. 14-я линия, д. 63

Natalia Yu. Samaneva – Cand. Sci. (Med.), junior researcher of the department of medicinal treatment of tumors, oncologist of the department of oncohematologySPIN: 1181-0659AuthorID: 734488ResearcherID: AAH-7905-2019Scopus Author ID: 57192874030

344037, Rostov-on-Don, 14 line str., 63

prettyfairy19@rambler.ruhttps://orcid.org/0000-0003-4457-3815ЛысенкоИ. Б.LysenkoI. B.

Лысенко Ирина Борисовна – д.м.н., профессор, заведующий отделением онкогематологииSPIN: 9510-3504AuthorID: 794669

г. Ростов-на-Дону

Irina B. Lysenko – Dr. Sci. (Med.), professor, head of the department of oncohematologySPIN: 9510-3504AuthorID: 794669

Rostov-on-Don

https://orcid.org/0000-0001-7224-3106НиколаеваН. В.NikolaevaN. V.

Николаева Надежда Владимировна – д.м.н., врач-гематолог отделения онкогематологии, ведущий научный сотрудник отдела лекарственного лечения опухолейSPIN: 4295-5920AuthorID: 733869

г. Ростов-на-Дону

Nadezhda V. Nikolaeva – Dr. Sci. (Med.), hematologist of the department of oncohematology, leading researcher at the department of drug treatment of tumorsSPIN: 4295-5920AuthorID: 733869

Rostov-on-Don

https://orcid.org/0000-0002-0761-2486КапузаЕ. А.KapuzaE. A.

Капуза Елена Анатольевна – врач-онколог отделения онкогематологииSPIN: 4430-1151AuthorID: 794666

г. Ростов-на-Дону

Elena A. Kapuza – MD, oncologist of the department of oncohematologySPIN: 4430-1151AuthorID: 794666

Rostov-on-Don

https://orcid.org/0000-0003-3001-0675КамаеваИ. А.KamaevaI. A.

Камаева Инна Анатольевна – врач-онколог отделения онкогематологии, младший научный сотрудник отдела лекарственного лечения опухолейSPIN: 8953-3351AuthorID: 937725

г. Ростов-на-Дону

Inna A. Kamaeva – MD, oncologist of the department of hematology, junior researcher of the department of drug treatment of tumorsSPIN:  8953-3351AuthorID: 937725

Rostov-on-Don

https://orcid.org/0000-0003-2785-1721ГайсултановаЯ. С.GaysultanovaY. S.

Гайсултанова Яха Сулеймановна – врач-онколог отделения онкогематологии

г. Ростов-на-Дону

Yakha S. Gaysultanova – MD, oncologist of the department of oncohematology

Rostov-on-Don

https://orcid.org/0000-0002-7990-8710ТишинаА. В.TishinaA. V.

Тишина Анна Викторовна – врач-онколог отделения онкогематологииSPIN: 7686-3707AuthorID: 965165ResearcherID: H-2460-2018

г. Ростов-на-Дону

Anna V. Tishina – MD, oncologist of the department of oncohematologySPIN: 7686-3707AuthorID: 965165ResearcherID: H-2460-2018

Rostov-on-Don

ПушкареваТ. Ф.PushkarevaT. F.

Пушкарева Татьяна Федоровна – врач-онколог клинико-диагностического отделенияSPIN: 8047-6830AuthorID: 801681

г. Ростов-на-Дону

Tatiana F. Pushkareva – MD, oncologist of the clinical and diagnostic departmentSPIN: 8047-6830AuthorID: 801681

Rostov-on-Don

 

НМИЦ онкологииРоссияNational Medical Research Centre for OncologyRussian Federation202231082022334147Copyright © Саманева Н.Ю., Лысенко И.Б., Николаева Н.В., Капуза Е.А., Камаева И.А., Гайсултанова Я.С., Тишина А.В., Пушкарева Т.Ф., 20222022Саманева Н.Ю., Лысенко И.Б., Николаева Н.В., Капуза Е.А., Камаева И.А., Гайсултанова Я.С., Тишина А.В., Пушкарева Т.Ф.Samaneva N.Y., Lysenko I.B., Nikolaeva N.V., Kapuza E.A., Kamaeva I.A., Gaysultanova Y.S., Tishina A.V., Pushkareva T.F.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.cancersp.com/jour/article/view/164

Лимфома Ходжкина – злокачественное заболевание лимфатической системы. Лимфома Ходжкина была впервые описана доктором Томасом Ходжкином в 1832 г., а позже названа «болезнью Ходжкина» Сэмюэлем Уилксом. Лимфома Ходжкина составляет около 24 % среди всех лимфом. Лимфома Ходжкина классифицируют как классическую и нодулярную с лимфоидным преобладанием (нодулярный тип лимфоидного преобладания лимфомы Ходжкина). Классическая лимфома Ходжкина включает следующие гистологические варианты: вариант с нодулярным склерозом (I и II типа), смешанно-клеточный вариант, классический вариант с большим количеством лимфоцитов и редко встречающийся вариант с лимфоидным истощением. Эпидемиологические и серологические исследования выявили причастность вируса Эпштейна-Барр к этиологии лимфомы Ходжкина: геном вируса Эпштейна-Барр был обнаружен при исследовании образцов биопсийного материала пациентов с лимфомой Ходжкина. Также выявлена связь с вирусом иммунодефицита человека (ВИЧ), заключающаяся в том, что пациенты, инфицированные ВИЧ, имеют значительно повышенный риск развития лимфомы Ходжкина по сравнению со здоровыми людьми. Углубленное изучение патофизиологии лимфомы Ходжкина позволило найти новые терапевтические мишени в лечении данного заболевания. Все эти открытия принесли изменения в понимании патогенеза данной патологии, и имеют важное значение в разработках новых методов лечения. История терапии начинается на рубеже XIX и XX вв. За последние четыре десятилетия достижения в лучевой терапии и использование комбинированной химиотерапии, значительно повысили уровень общей выживаемости пациентов с лимфомой Ходжкина. В настоящее время более 80 % пациентов моложе 60 лет с впервые диагностированной лимфомой Ходжкина могут быть излечены от данного заболевания после проведения первой линии химиотерапии.

Hodgkin's lymphoma is a malignant disease of the lymphatic system. Hodgkin's lymphoma was first described by Dr. Thomas Hodgkin in 1832 and later named “Hodgkin's disease” by Samuel Wilkes. Hodgkin's lymphoma accounts for about 24 % of all lymphomas. Hodgkin's lymphoma is classified as classical and nodular lymphoid-predominant (Nodular type of lymphoidpredominant Hodgkin's lymphoma). Classical Hodgkin's lymphoma includes the following histologic variants: nodular sclerosis variant (types I and II), mixed cell variant, classic lymphocyte-rich variant, and rare lymphoid depletion variant. Epidemiological and serological studies showed the involvement of the Epstein-Barr virus into Hodgkin's lymphoma etiology, since its genome was found in the study of the biopsy material samples from patients with Hodgkin's lymphoma. A relationship with the human immunodeficiency virus (HIV) was revealed as well, and patients infected with HIV have a significantly increased risk of developing Hodgkin's lymphoma compared to healthy people. An in-depth study of the Hodgkin's lymphoma pathophysiology revealed new therapeutic targets in the treatment of this disease. All these discoveries changed the understanding of the Hodgkin's lymphoma pathogenesis, and were important for the development of new methods of treatment. The history of therapy begins on the cusp of the 19th and 20th centuries. Over the past four decades, achievements in radiation therapy and combined chemotherapy have significantly improved overall survival of patients with Hodgkin's lymphoma. Currently, more than 80 % of patients under 60 years old with first diagnosed Hodgkin's lymphoma can be cured from this disease after first-line chemotherapy.

лимфома ХоджкинаВИЧвирус Эпштейна-БаррИГХремиссияпрогрессированиерезистентность к химиотерапииобщая выживаемостьHodgkin lymphomaHIVEpstein-Barr virusIHCremissionprogressionchemotherapy resistanceoverall survivalReferencesHodgkin null. On some Morbid Appearances of the Absorbent Glands and Spleen. Med Chir Trans. 1832;17:68–114. https://doi.org/10.1177/095952873201700106Hodgkin null. On some Morbid Appearances of the Absorbent Glands and Spleen. Med Chir Trans. 1832;17:68–114. https://doi.org/10.1177/095952873201700106Gemici A, Aydogdu I, Terzi H, Sencan M, Aslan A, Kaya AH, et al. Nodular lymphocyte predominant Hodgkin’s lymphoma in daily practice: A multicenter experience. Hematol Oncol. 2018 Feb;36(1):116–120. https://doi.org/10.1002/hon.2460Gemici A, Aydogdu I, Terzi H, Sencan M, Aslan A, Kaya AH, et al. Nodular lymphocyte predominant Hodgkin’s lymphoma in daily practice: A multicenter experience. Hematol Oncol. 2018 Feb;36(1):116–120. https://doi.org/10.1002/hon.2460Злокачественные новообразования в России в 2017 году (заболеваемость и смертность). Под ред. А. Д. Каприна, В. В. Старинского, Г. В. Петровой. М.: МНИОИ им. П. А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2018, 250 с.Malignant neoplasms in Russia in 2017 (morbidity and mortality). Ed. by A. D. Kaprin, V. V. Starinsky, G. V. Petrova. Moscow: P. A. Herzen Moscow State Medical Research Institute – Branch of the Federal State Budgetary Institution "NMIC of Radiology" of the Ministry of Health of Russia, 2018, 250 p. (In Russ.).Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon, France: International Agency for Research in Cancer (IARC). 2017, 585 p.Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon, France: International Agency for Research in Cancer (IARC). 2017, 585 p.Devita VT, Serpick AA, Carbone PP. Combination chemotherapy in the treatment of advanced Hodgkin’s disease. Ann Intern Med. 1970 Dec;73(6):881–895. https://doi.org/10.7326/0003-4819-73-6-881Devita VT, Serpick AA, Carbone PP. Combination chemotherapy in the treatment of advanced Hodgkin’s disease. Ann Intern Med. 1970 Dec;73(6):881–895. https://doi.org/10.7326/0003-4819-73-6-881Horning SJ, Rosenberg SA, Hoppe RT. Brief chemotherapy (Stanford V) and adjuvant radiotherapy for bulky or advanced Hodgkin’s disease: an update. Ann Oncol. 1996;7 Suppl 4:105–108. https://doi.org/10.1093/annonc/7.suppl_4.s105Horning SJ, Rosenberg SA, Hoppe RT. Brief chemotherapy (Stanford V) and adjuvant radiotherapy for bulky or advanced Hodgkin’s disease: an update. Ann Oncol. 1996;7 Suppl 4:105–108. https://doi.org/10.1093/annonc/7.suppl_4.s105Merli F, Luminari S, Gobbi PG, Cascavilla N, Mammi C, Ilariucci F, et al. Long-Term Results of the HD2000 Trial Comparing ABVD Versus BEACOPP Versus COPP-EBV-CAD in Untreated Patients With Advanced Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi. J Clin Oncol. 2016 Apr 10;34(11):1175–1181. https://doi.org/10.1200/JCO.2015.62.4817Merli F, Luminari S, Gobbi PG, Cascavilla N, Mammi C, Ilariucci F, et al. Long-Term Results of the HD2000 Trial Comparing AB-VD Versus BEACOPP Versus COPP-EBV-CAD in Untreated Patients With Advanced Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi. J Clin Oncol. 2016 Apr 10;34(11):1175–1181. https://doi.org/10.1200/JCO.2015.62.4817Gordon LI, Hong F, Fisher RI, Bartlett NL, Connors JM, Gascoyne RD, et al. Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496). J Clin Oncol. 2013 Feb 20;31(6):684–691. https://doi.org/10.1200/JCO.2012.43.4803Gordon LI, Hong F, Fisher RI, Bartlett NL, Connors JM, Gascoyne RD, et al. Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496). J Clin Oncol. 2013 Feb 20;31(6):684–691. https://doi.org/10.1200/JCO.2012.43.4803Viviani S, Zinzani PL, Rambaldi A, Brusamolino E, Levis A, Bonfante V, et al. ABVD versus BEACOPP for Hodgkin’s lymphoma when high-dose salvage is planned. N Engl J Med. 2011 Jul 21;365(3):203–212. https://doi.org/10.1056/NEJMoa1100340Viviani S, Zinzani PL, Rambaldi A, Brusamolino E, Levis A, Bonfante V, et al. ABVD versus BEACOPP for Hodgkin’s lymphoma when high-dose salvage is planned. N Engl J Med. 2011 Jul 21;365(3):203–212. https://doi.org/10.1056/NEJMoa1100340Eichenauer DA, Engert A. The evolving role of targeted drugs in the treatment of Hodgkin lymphoma. Expert Rev Hematol. 2017 Sep;10(9):775–782. https://doi.org/10.1080/17474086.2017.1350167Eichenauer DA, Engert A. The evolving role of targeted drugs in the treatment of Hodgkin lymphoma. Expert Rev Hematol. 2017 Sep;10(9):775–782. https://doi.org/10.1080/17474086.2017.1350167Moskowitz AJ, Schöder H, Yahalom J, McCall SJ, Fox SY, Gerecitano J, et al. PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin’s lymphoma: a non-randomised, open-label, single-centre, phase 2 study. Lancet Oncol. 2015 Mar;16(3):284–292. https://doi.org/10.1016/S1470-2045(15)70013-6Moskowitz AJ, Schöder H, Yahalom J, McCall SJ, Fox SY, Gerecitano J, et al. PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin’s lymphoma: a non-randomised, open-label, single-centre, phase 2 study. Lancet Oncol. 2015 Mar;16(3):284–292. https://doi.org/10.1016/S1470-2045(15)70013-6Kumar A, Casulo C, Yahalom J, Schöder H, Barr PM, Caron P, et al. Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma. Blood. 2016 Sep 15;128(11):1458–1464. https://doi.org/10.1182/blood-2016-03-703470Kumar A, Casulo C, Yahalom J, Schöder H, Barr PM, Caron P, et al. Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma. Blood. 2016 Sep 15;128(11):1458–1464. https://doi.org/10.1182/blood-2016-03-703470Böll B, Borchmann P, Topp MS, Hänel M, Reiners KS, Engert A, et al. Lenalidomide in patients with refractory or multiple relapsed Hodgkin lymphoma. Br J Haematol. 2010 Feb;148(3):480–482. https://doi.org/10.1111/j.1365-2141.2009.07963.xBöll B, Borchmann P, Topp MS, Hänel M, Reiners KS, Engert A, et al. Lenalidomide in patients with refractory or multiple relapsed Hodgkin lymphoma. Br J Haematol. 2010 Feb;148(3):480–482. https://doi.org/10.1111/j.1365-2141.2009.07963.xJohnston PB, Inwards DJ, Colgan JP, Laplant BR, Kabat BF, Habermann TM, et al. A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. Am J Hematol. 2010 May;85(5):320–324. https://doi.org/10.1002/ajh.21664Johnston PB, Inwards DJ, Colgan JP, Laplant BR, Kabat BF, Habermann TM, et al. A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. Am J Hematol. 2010 May;85(5):320–324. https://doi.org/10.1002/ajh.21664Horie R, Watanabe T. CD30: expression and function in health and disease. Semin Immunol. 1998 Dec;10(6):457–470. https://doi.org/10.1006/smim.1998.0156Horie R, Watanabe T. CD30: expression and function in health and disease. Semin Immunol. 1998 Dec;10(6):457–470. https://doi.org/10.1006/smim.1998.0156Younes A, Santoro A, Shipp M, Zinzani PL, Timmerman JM, Ansell S, et al. Nivolumab for classical Hodgkin’s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol. 2016 Sep;17(9):1283–1294. https://doi.org/10.1016/S1470-2045(16)30167-XYounes A, Santoro A, Shipp M, Zinzani PL, Timmerman JM, Ansell S, et al. Nivolumab for classical Hodgkin’s lymphoma af- ter failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol. 2016 Sep;17(9):1283–1294. https://doi.org/10.1016/S1470-2045(16)30167-XAnsell S, Bröckelmann P, Keudell G von, Lee HJ, Santoro A, Zinzani PL, et al. HL-398: Five-Year Overall Survival from the CheckMate 205 Study of Nivolumab for Relapsed or Refractory (R/R) Classical Hodgkin Lymphoma (cHL). Clinical Lymphoma, Myeloma and Leukemia. 2021 Sep 1;21:S373–S374. https://doi.org/10.1016/S2152-2650(21)01854-1Ansell S, Bröckelmann P, Keudell G von, Lee HJ, Santoro A, Zinzani PL, et al. HL-398: Five-Year Overall Survival from the CheckMate 205 Study of Nivolumab for Relapsed or Refractory (R/R) Classical Hodgkin Lymphoma (cHL). Clinical Lymphoma, Myeloma and Leukemia. 2021 Sep 1;21:S373–S374. https://doi.org/10.1016/S2152-2650(21)01854-1Ilcus C, Bagacean C, Tempescul A, Popescu C, Parvu A, Cenariu M, et al. Immune checkpoint blockade: the role of PD-1-PD-L axis in lymphoid malignancies. Onco Targets Ther. 2017;10:2349–2363. https://doi.org/10.2147/OTT.S133385Ilcus C, Bagacean C, Tempescul A, Popescu C, Parvu A, Cenariu M, et al. Immune checkpoint blockade: the role of PD-1-PD-L axis in lymphoid malignancies. Onco Targets Ther. 2017;10:2349–2363. https://doi.org/10.2147/OTT.S133385Killock D. CAR T cells are active in Hodgkin lymphoma. Nat Rev Clin Oncol. 2020 Oct;17(10):592. https://doi.org/10.1038/s41571-020-0425-8Killock D. CAR T cells are active in Hodgkin lymphoma. Nat Rev Clin Oncol. 2020 Oct;17(10):592. https://doi.org/10.1038/s41571-020-0425-8

The authors declare that there are no conflicts of interest present.